---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000053"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:14:43.285653+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ligand acquires APEIRON for $100M, adds QARZIBA royalty; raises 2024 guidance

## Summary
- Acquisition of APEIRON Biologics for $100M cash; up to $28M additional contingent consideration based on QARZIBA royalty thresholds by 2030/2034.
- QARZIBA is approved in EU for high-risk neuroblastoma, marketed in >35 countries by Recordati; patent protection until 2034.
- Transaction expected to close July 2024; subject to 30-day shareholder objection period and other customary conditions.
- Ligand raises 2024 revenue guidance to $140M-$157M (from $130M-$142M) and core adjusted EPS to $5.00-$5.50 (from $4.25-$4.75).
- Deal immediately accretive to EPS by ~$1.00 annualized; ~$0.50 impact in 2024.

## SEC filing metadata
- accession: 0000886163-24-000053
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/0000886163-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/lgnd-20240708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000053
- JSON: https://secwatch.observer/filing/0000886163-24-000053.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.